GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Current Ratio

Genprex (Genprex) Current Ratio : 2.42 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genprex Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Genprex's current ratio for the quarter that ended in Mar. 2024 was 2.42.

Genprex has a current ratio of 2.42. It generally indicates good short-term financial strength.

The historical rank and industry rank for Genprex's Current Ratio or its related term are showing as below:

GNPX' s Current Ratio Range Over the Past 10 Years
Min: 0.23   Med: 7.64   Max: 61.43
Current: 2.31

During the past 9 years, Genprex's highest Current Ratio was 61.43. The lowest was 0.23. And the median was 7.64.

GNPX's Current Ratio is ranked worse than
64.46% of 1553 companies
in the Biotechnology industry
Industry Median: 3.79 vs GNPX: 2.31

Genprex Current Ratio Historical Data

The historical data trend for Genprex's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Current Ratio Chart

Genprex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only 5.83 61.43 24.69 7.64 2.31

Genprex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.12 3.20 2.96 2.31 2.42

Competitive Comparison of Genprex's Current Ratio

For the Biotechnology subindustry, Genprex's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genprex's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's Current Ratio distribution charts can be found below:

* The bar in red indicates where Genprex's Current Ratio falls into.



Genprex Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Genprex's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=7.532/3.254
=2.31

Genprex's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=9.228/3.808
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genprex  (NAS:GNPX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Genprex Current Ratio Related Terms

Thank you for viewing the detailed overview of Genprex's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genprex (Genprex) Business Description

Traded in Other Exchanges
Address
3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746
Genprex Inc is a clinical-stage gene therapy company. It is a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.
Executives
Catherine M Vaczy officer: EVP & Chief Strategy Officer C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner director, 10 percent owner, officer: Chief Executive Officer P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar officer: Chief Mfgr & Tech Officer 3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger officer: Chief Medical Officer 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker director C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio director 1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr. director 1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman officer: EVP & Chief Operating Officer 16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc. director, 10 percent owner, officer: Chief Executive Officer 1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham officer: Chief Operating Officer 944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth 10 percent owner 6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance 10 percent owner 8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer officer: Chief Financial Officer 1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson director 3001 MEANDERING RIVER COURT, AUSTIN TX 78746

Genprex (Genprex) Headlines

From GuruFocus